---
layout: default
title: Reslizumab
parent: AI Predictions (L5)
nav_order: 501
evidence_level: L5
indication_count: 10
---

# Reslizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Reslizumab: From Undocumented Original Indication to Thrombocytopenia Due to Immune Destruction

## One-Sentence Summary

> Reslizumab's original approved indication and detailed mechanism-of-action are not recorded in this evidence pack, and the drug is not currently marketed in the EU per this dataset. TxGNN's top-ranked prediction is efficacy for **Thrombocytopenia Due to Immune Destruction** (score 99.53%), but this candidate is currently supported by **0 clinical trials** and **0 publications**, and the model's own mechanistic annotation flags it as likely reflecting knowledge-graph structural similarity rather than a genuine biological pathway.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available — no license or indication data on file |
| Predicted New Indication | Thrombocytopenia Due to Immune Destruction |
| TxGNN Prediction Score | 99.53% (raw graph rank #5,237) |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for reslizumab is not available in this evidence pack. The only mechanistic information on file comes from the prediction's own rationale text, which notes that reslizumab's known action is IL-5 blockade, primarily affecting eosinophils.

The rationale explicitly states that there is **no established mechanistic connection** between IL-5/eosinophil biology and immune-mediated platelet destruction (which is driven by anti-platelet autoantibodies and Fc-receptor-mediated clearance by macrophages). It further notes that the high TxGNN score likely reflects structural similarity between biologic-drug and autoimmune-disease nodes within the knowledge graph, rather than a true, validated biological pathway.

In short, despite the numerically high prediction score, the evidence pack's own scoring assigns this candidate **L5 (model prediction only, no supporting studies)** and a **Hold** recommendation — this is a data-driven signal without current biological or clinical corroboration.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the SmPC for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (Thrombocytopenia Due to Immune Destruction) has zero clinical trial or literature support, and the pack's own mechanistic assessment argues against biological plausibility. Drug-level regulatory data (TFDA label warnings/contraindications) is also flagged as a **Blocking** gap (DG001), which by itself prevents advancing this candidate to any safety review stage.

**To proceed, the following is needed:**
- TFDA/EMA label warnings and contraindications (DG001, Blocking) — required before any S1 safety screening
- Confirmed mechanism of action and original approved indication(s) for reslizumab (DG002, High)
- Independent biological/preclinical evidence linking IL-5 blockade to immune platelet destruction, since none currently exists

**Note on other candidates in this evidence pack:**
This pack ("TW-DB06602-multi") evaluated 10 predicted indications for reslizumab. Nine of them — including the top-ranked one above — have no supporting clinical trials or literature (L5, Hold). One exception stands out: **filariasis** (rank 9, TxGNN score 96.22%, rank #29,004) is supported by a completed Phase 2, randomized, placebo-controlled trial ([NCT01111305](https://clinicaltrials.gov/study/NCT01111305), n=31) and 2 PubMed articles, evaluating reslizumab's use in reducing IL-5-dependent eosinophilia-related adverse reactions following diethylcarbamazine treatment of Loa loa infection (loiasis). This candidate is scored **L2 / S2 / Research Question** and, despite its lower raw TxGNN score, is mechanistically well-supported and may warrant a separate, dedicated evaluation report.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

